AML (ACUTE MYELOID LEUKEMIA)
Clinical trials for AML (ACUTE MYELOID LEUKEMIA) explained in plain language.
Never miss a new study
Get alerted when new AML (ACUTE MYELOID LEUKEMIA) trials appear
Sign up with your email to follow new studies for AML (ACUTE MYELOID LEUKEMIA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to boost remission in tough AML cases
Disease control Not yet recruitingThis study tests a new combination of drugs (chidamide, venetoclax, azacitidine, and homoharringtonine) as a first treatment for adults aged 18-60 with intermediate- to high-risk acute myeloid leukemia (AML). The goal is to see if this mix can improve remission rates and reduce t…
Matched conditions: AML (ACUTE MYELOID LEUKEMIA)
Phase: PHASE2 • Sponsor: Dongguan People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immune cell boost may keep leukemia at bay after transplant
Disease control Not yet recruitingThis study tests a stem cell transplant from a matched sibling donor combined with special immune cells (regulatory and conventional T cells) for people with high-risk acute myeloid leukemia (AML). The goal is to prevent the cancer from coming back. About 28 participants will rec…
Matched conditions: AML (ACUTE MYELOID LEUKEMIA)
Phase: PHASE2 • Sponsor: Antonio Pierini • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New combo aims to outdo standard chemo for FLT3-Mutated leukemia
Disease control Not yet recruitingThis study tests a new three-drug combination (gilteritinib, azacitidine, and venetoclax) against standard chemotherapy for adults with a specific genetic subtype of acute myeloid leukemia (FLT3-ITD). About 230 newly diagnosed patients aged 18-75 who are healthy enough for intens…
Matched conditions: AML (ACUTE MYELOID LEUKEMIA)
Phase: PHASE2, PHASE3 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Engineered immune cells take on tough leukemia in new trial
Disease control Not yet recruitingThis early-phase study tests a new type of CAR-T cell therapy for adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to better find and attack leukemia cells. The main goal i…
Matched conditions: AML (ACUTE MYELOID LEUKEMIA)
Phase: PHASE1, PHASE2 • Sponsor: Xuzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo attack for tough leukemia: CAR-T cells then transplant
Disease control Not yet recruitingThis study tests a two-step treatment for people with acute myeloid leukemia (AML) that has come back or not responded to standard chemo. First, patients receive CLL1 CAR-T cells (engineered immune cells that target leukemia). Then they get a stem cell transplant from a donor. Th…
Matched conditions: AML (ACUTE MYELOID LEUKEMIA)
Phase: NA • Sponsor: Donghua Zhang • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Experimental CAR-T therapy targets tough childhood leukemia
Disease control Not yet recruitingThis early-phase study tests a new treatment called CLL-1 CAR-T for children aged 3 to 18 with acute myeloid leukemia that has come back or not responded to standard therapy. Ten participants will receive an infusion of their own modified immune cells after chemotherapy. The main…
Matched conditions: AML (ACUTE MYELOID LEUKEMIA)
Phase: EARLY_PHASE1 • Sponsor: First Affiliated Hospital of Guangxi Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New hope for frail AML patients: less toxic drug combo shows promise
Disease control Not yet recruitingThis study tests a new drug combination using selinexor with fewer or no harsh chemo drugs for adults newly diagnosed with acute myeloid leukemia (AML) who are too frail for standard intensive chemo. The goal is to quickly reduce leukemia cells while causing fewer side effects. A…
Matched conditions: AML (ACUTE MYELOID LEUKEMIA)
Phase: NA • Sponsor: Donghua Zhang • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New transplant prep aims to boost survival in leukemia patients
Disease control Not yet recruitingThis phase 2 trial tests whether adding venetoclax to standard chemotherapy before a stem cell transplant can improve survival for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The study will enroll 27 adults aged 18 to 75. The main goal is…
Matched conditions: AML (ACUTE MYELOID LEUKEMIA)
Phase: PHASE2 • Sponsor: University Hospital Tuebingen • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New dual CAR-T attack on tough leukemia shows early promise
Disease control Not yet recruitingThis early-phase trial tests a two-step treatment for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. First, patients receive special immune cells (CAR-T cells) that target two markers on leukemia cells, followed by a second type …
Matched conditions: AML (ACUTE MYELOID LEUKEMIA)
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New trial aims to find safer chemo for stem cell transplants in leukemia patients
Disease control Not yet recruitingThis study tests two chemotherapy drugs, treosulfan and melphalan, given before a stem cell transplant in 220 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to see which drug works better at helping patients survive longer with fewer side …
Matched conditions: AML (ACUTE MYELOID LEUKEMIA)
Phase: PHASE2 • Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Jun 26, 2026 12:47 UTC